Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity.
Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics.
Purchase orders from multiple contract manufacturing customers have a combined value of more than $3.2M.
CAP accreditation is widely recognized as a mark of laboratory quality and operational excellence.
Brand consolidation strengthens Renew’s ability to move advanced molecular technologies from discovery to clinical implementation.
KyphoLift is gaining attention as hospitals and imaging centers prepare for federal accessibility requirements.
Marks an important milestone with a ribbon-cutting ceremony celebrating the completion of an expansive new distribution center.
Trial Reports 99% Successful Occlusion of Flow with 40 Investigators Delivering the New Embolic Through 20 Different Catheters.
Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics.
INTEGUMENT-INFANT showed 49.1% achieving vIGA-AD clear/almost clear at week 4 and 27.3% meeting vIGA-AD Success, alongside rapid pruritus improvement.
resentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases.
Physician and U.S. Rep. Mike Kennedy (R-UT) toured the Edwards Lifesciences plant in Draper, UT, on Wednesday.